Sulphonylureas and cancer: A case-control study

Acta Diabetologica

Volumn 46, Issue 4, 2009, Pages 279-284

  Monami, Matteo ^a   Lamanna, Caterina ^a   Balzi, Daniela ^b   Marchionni, Niccolò ^a   Mannucci, Edoardo ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Local Health Unit 10   (Italy)

Author keywords

Cancer; Case control study; Diabetes mellitus; Hypoglycaemic Drugs; Sulphonylureas

Indexed keywords

ACARBOSE; ALCOHOL; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT RECEPTOR; CHLORPROPAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PHENFORMIN; REPAGLINIDE; SULFONYLUREA; TOLBUTAMIDE;

ADULT; AGED; ALCOHOL ABUSE; ARTICLE; BODY MASS; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DIABETIC PATIENT; DIGESTIVE SYSTEM CANCER; DISEASE DURATION; ESOPHAGUS CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; HUMAN; INTESTINE CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION; SMOKING; STOMACH CANCER; UTERINE CERVIX CANCER; UTERUS CANCER;

AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLICLAZIDE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NEOPLASMS; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 70449533135     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-008-0083-2     Document Type: Article

References (18)

1. SL Bowker SR Majumdar P Veugelers JA Johnson 2006 Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin Diabetes Care 29 254 258 10.2337/diacare.29.02.06.dc05-1558 16443869
2. M Monami D Balzi C Lamanna, et al.. 2007 Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality Diabetes Metab Res Rev 23 479 484 10.1002/dmrr.736 1:STN:280:DC%2BD2srhtlSjug%3D%3D 17385195 (Pubitemid 47520905)
3. A Sliwinska J Blasiak J Drzewoski 2006 Effect of gliclazide on DNA damage in human peripheral blood lymphocytes and insulinoma mouse cells Chem Biol Interact 162 259 267 10.1016/j.cbi.2006.07.006 1:CAS:528:DC%2BD28XpvFeks70%3D 16963009 (Pubitemid 44402413)
4. WHO (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech.Rep.Ser. 894:i-253
5. J Chalmers S MacMahon G Mancia, et al.. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension: guidelines sub-committee of the World Health Organization Clin Exp Hypertens 21 1009 1060 10.3109/10641969909061028 1:STN:280: DyaK1MzkvF2rtg%3D%3D 10423121
6. M Charlson T Szatrowski T Peterson J Gold 1994 Validation of a combined comorbidity index J Clin Epidemiol 47 1245 1251 10.1016/0895-4356(94)90129-5 1:STN:280:DyaK2M3jvFantQ%3D%3D 7722560 (Pubitemid 24361532)
7. E Mannucci M Monami G Masotti N Marchionni 2004 All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides Diabetes Metab Res Rev 20 44 47 10.1002/dmrr.411 1:CAS:528:DC%2BD2cXhvFehsL0%3D 14737744 (Pubitemid 38196247)
8. M Pahor JM Guralnik L Ferrucci MC Corti ME Salive JR Cerhan, et al.. 1996 Calcium-channel blockade and incidence of cancer in aged populations Lancet 348 493 497 10.1016/S0140-6736(96)04277-8 1:CAS:528:DyaK28Xls1Gltbg%3D 8757150 (Pubitemid 26279010)
9. L Rosenberg RS Rao JR Palmer BL Strom PD Stolley AG Zauber ME Warshauer S Shapiro 1998 Calcium channel blockers and the risk of cancer JAMA 279 1000 1004 10.1001/jama.279.13.1000 1:STN:280:DyaK1c7pt1Wluw%3D%3D 9533498 (Pubitemid 28172998)
10. S Friis HT Sørensen L Mellemkjaer JK McLaughlin GL Nielsen WJ Blot JH Olsen 2001 Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark Cancer 92 2462 2470 10.1002/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L 1:CAS:528:DC%2BD3MXotl2itbs%3D 11745304 (Pubitemid 33029093)
11. JM Evans LA Donnelly AM Emslie-Smith DR Alessi AD Morris 2005 Metformin and reduced risk of cancer in diabetic patients BMJ 330 1304 1305 10.1136/bmj.38415.708634.F7 15849206 (Pubitemid 40813563)
12. M Monami C Luzzi C Lamanna, et al.. 2006 Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin Diabetes Metab Res Rev 22 477 482 10.1002/dmrr.642 1:CAS:528:DC%2BD28Xhtlemu7%2FK 16634115 (Pubitemid 44774052)
13. ME Ramos-Nino CD Maclean B Littenberg 2007 Association between cancer prevalence and use of thiazolidinediones (TZDs): results from the vermont diabetes information system BMC Med 5 17 23 10.1186/1741-7015-5-17 17584937 (Pubitemid 47226207)
14. Monami M, Lamanna C, Marchionni N, Mannucci E (2008) Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care Epub ahead of print
15. UK Prospective Diabetes Study (UKPDS) Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837 853 10.1016/S0140-6736(98)07019-6 (Pubitemid 28416718)
16. SE Kahn SM Haffner MA Heise, et al.. 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2427 2443 10.1056/NEJMoa066224 1:CAS:528:DC%2BD28Xht12ntrzF 17145742 (Pubitemid 44903747)
17. PD Home SJ Pocock H Beck-Nielsen, et al.. 2007 Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis N Engl J Med 357 28 38 10.1056/NEJMoa073394 1:CAS:528:DC%2BD2sXnsVCqs7w%3D 17551159 (Pubitemid 47026732)
18. ADVANCE study group (2001) Study rationale and design of ADVANCE: action in diabetes and vascular disease-preterax and diamicron MR controlled evaluation. Diabetologia 44:1118-1120